HomeCompareARCAY vs JNJ

ARCAY vs JNJ: Dividend Comparison 2026

ARCAY yields 3.62% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ARCAY wins by $1070.17M in total portfolio value
10 years
ARCAY
ARCAY
● Live price
3.62%
Share price
$30.00
Annual div
$1.09
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1070.20M
Annual income
$1,016,270,545.18
Full ARCAY calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — ARCAY vs JNJ

📍 ARCAY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodARCAYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ARCAY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ARCAY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ARCAY
Annual income on $10K today (after 15% tax)
$307.70/yr
After 10yr DRIP, annual income (after tax)
$863,829,963.40/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, ARCAY beats the other by $863,825,926.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ARCAY + JNJ for your $10,000?

ARCAY: 50%JNJ: 50%
100% JNJ50/50100% ARCAY
Portfolio after 10yr
$535.12M
Annual income
$508,137,647.53/yr
Blended yield
94.96%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ARCAY
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
4.3
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ARCAY buys
0
JNJ buys
0
No recent congressional trades found for ARCAY or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricARCAYJNJ
Forward yield3.62%2.14%
Annual dividend / share$1.09$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$1070.20M$30.5K
Annual income after 10y$1,016,270,545.18$4,749.88
Total dividends collected$1066.30M$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: ARCAY vs JNJ ($10,000, DRIP)

YearARCAY PortfolioARCAY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,424$724.00$10,594$274.49+$830.00ARCAY
2$13,770$1,545.98$11,294$360.69+$2.5KARCAY
3$18,217$3,483.01$12,133$476.91+$6.1KARCAY
4$28,104$8,612.77$13,156$635.42+$14.9KARCAY
5$54,909$24,836.98$14,432$854.61+$40.5KARCAY
6$149,453$90,700.85$16,056$1,162.76+$133.4KARCAY
7$621,361$461,446.30$18,175$1,604.53+$603.2KARCAY
8$4,250,823$3,585,966.72$21,009$2,252.68+$4.23MARCAY
9$50,402,817$45,854,436.20$24,911$3,229.73+$50.38MARCAY
10$1,070,201,559$1,016,270,545.18$30,458$4,749.88+$1070.17MARCAY

ARCAY vs JNJ: Complete Analysis 2026

ARCAYStock

Arcadis NV operates as a design and consultancy firm for natural and built assets worldwide. The company operates through four segments: Europe & Middle East, The Americas, Asia Pacific, and CallisonRTKL. It offers architectural based design consultancy services; and asset management services, such as asset management strategy and planning, asset management decision making and operational optimization, life cycle planning and asset management systems, asset information/condition assessment, risk and review, organization and people, and asset management/O&M. The company also provides business advisory services, including asset strategy and performance, business transformation and resiliency, investment and finance, operations and maintenance, and technology and information; cost and commercial management services; and design and engineering solutions for highways, railways, bridges, tunnels, power utilities, water utilities, ports and waterways, geotechnics, architecture, and structures, as well as building mechanical, electrical, and plumbing. In addition, it offers digital environmental health safety and sustainability, environmental restoration, and project management solutions. Further, the company provides mobility solutions for connected highways, intelligent rail and transit, integrated airports, and new mobility; places solutions; resilience solutions, including climate adaption, energy transition, enviro socio permitting, environmental restoration, sustainable advisory, sustainable operations, and water optimization; and water supply and treatment, distribution, resource management, and industrial water and wastewater services. It serves industrial manufacturing, technology, property and investment, contractors, and energy and resources sectors. The company was formerly known as Heidemij NV and changed its name to Arcadis N.V. in October 1997. Arcadis NV was founded in 1888 and is headquartered in Amsterdam, the Netherlands.

Full ARCAY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this ARCAY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ARCAY vs SCHDARCAY vs JEPIARCAY vs OARCAY vs KOARCAY vs MAINARCAY vs ABBVARCAY vs MRKARCAY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.